InspireMD develops and commercializes carotid stent systems built around its MicroNet stent platform for carotid artery disease and stroke prevention. News for NSPR centers on CGuard Prime and CGuard product commercialization, U.S. and international demand, FDA interactions, IDE approvals, pivotal studies for TCAR-related use, and product quality actions such as the CGuard Prime 135 cm delivery-system recall.
Company updates also cover quarterly financial results, hospital adoption and procedure experience, publications from C-GUARDIANS studies, investor conference participation, and capital-market communications tied to its Nasdaq-listed common stock.
InspireMD reported a substantial revenue increase of 149.2% for Q1 2020, totaling $1,034,000, driven mainly by strong sales of the CGuard™ Embolic Prevention System (EPS), which rose 158.2% to $971,000. The company also noted a recovery from third-party sterilizer failures that impacted previous sales. Gross profit improved to $295,000 compared to a gross loss last year, with a gross margin of 28.5%. Despite a net loss of $1,978,000, cash reserves were reported at $3,141,000. InspireMD aims to expand its product offerings and market reach.